Sarepta Therapeutics Announces Third Quarter 2015 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Sarepta (SRPT) Conditional-Approval Thesis Unchanged, Roth Capital Says
November 6, 2015 8:17 AM ESTRoth Capital analyst Debjit Chattopadhyay reiterated a Buy rating and $50 price target on Sarepta Therapeutic (NASDAQ: SRPT), saying their conditional-approval thesis remains unchanged.
Chattopadhyay commented, "A new therapy is not considered available therapy if granted accelerated approval based on a surrogate or... More
Needham & Company Maintain High Conviction for Sarepta (SRPT) Eteplirsen Approval
November 6, 2015 6:53 AM ESTNeedham & Company analyst Chad Messer reiterated a Buy rating and $50 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying they maintain high conviction in Eteplirsen approval.
Messer commented, "SRPT shares have pulled back from recent highs due to concerns that etelpirsen's later than expected... More
Sarepta Therapeutics (SRPT) Tops Q3 EPS by 7c
November 5, 2015 7:04 AM ESTSarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($1.11), $0.07 better than the analyst estimate of ($1.18).
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.
... More